Mary E D'Alton

Society for Maternal-Fetal Medicine, New York, New York, United States

Are you Mary E D'Alton?

Claim your profile

Publications (193)1097.98 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The rise in maternal morbidity and mortality has resulted in national and international attention at optimally organizing systems and teams for pregnancy care. Given that maternal morbidity and mortality can occur unpredictably in any obstetric setting, specialists in general obstetrics and gynecology along with other primary maternal care providers should be integrally involved in efforts to improve the safety of obstetric care delivery. Quality improvement initiatives remain vital to meeting this goal. The evidence-based utilization of triggers, bundles, protocols, and checklists can aid in timely diagnosis and treatment to prevent or limit the severity of morbidity as well as facilitate interdisciplinary, patient-centered care. The purpose of this document is to summarize the pertinent elements from this forum to assist primary maternal care providers in their utilization and implementation of these safety tools.
    American journal of obstetrics and gynecology 10/2015; DOI:10.1016/j.ajog.2015.10.011 · 4.70 Impact Factor
  • K L Palmerola · M E D'Alton · C O Brock · A M Friedman ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Guidelines for pharmacologic obstetric venous thromboembolism (VTE) prophylaxis from the American Congress of Obstetricians (ACOG), the Royal College of Obstetricians and Gynaecologists (RCOG), and the American College of Chest Physicians (Chest) vary significantly. The objective of this study was to determine the practical implications of these recommendations in terms of prophylaxis rates for a tertiary obstetric population. Cross-sectional. Tertiary referral hospital. Patients post-operative day 1 after caesarean delivery. This cross-sectional study evaluated rates of pharmacologic prophylaxis for women based on RCOG, ACOG, and Chest recommendations. Medical, obstetric, and demographic risk factors for thromboembolism were reviewed for individual patients. Rates of prophylaxis based on each of the guidelines with 95% confidence intervals were calculated. Recommended pharmacologic prophylaxis. About 293 patients were included in the analysis. Under RCOG guidelines, 85.0% of patients would receive post-caesarean pharmacologic prophylaxis [95% confidence interval (CI) 80.5–88.6%] compared with 1.0% of patients under ACOG guidelines (95% CI 0.3–3.0%) and 34.8% of patients under Chest guidelines (95% CI 29.6–40.4%). Caesarean during labour, obesity, advanced maternal age, pre-eclampsia, and multiple gestation were among the most commonrisk factors. Recommended prophylaxis differed significantly. Under ACOG recommendations a small minority of patients would receive prophylaxis, whereas under RCOG recommendations a large majority of patients would receive low-molecular-weight heparin. Given the large differences in prophylaxis rates for post-caesarean thromboprophylaxis based on different guidelines, further research is urgently needed to compare the risks and benefits of recommendations. Recommendations from major society guidelines for post-caesarean thromboprophylaxis differ greatly.
    BJOG An International Journal of Obstetrics & Gynaecology 10/2015; DOI:10.1111/1471-0528.13706 · 3.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fetomaternal hemorrhage (FMH) can be associated with significant perinatal mortality. Our review of the literature did not identify any cases of FMH following placement of an intrauterine pressure catheter (IUPC). In our case, an IUPC was inserted in a patient undergoing induction of labor at term. Fetal bradycardia ensued shortly after placement, warranting an emergent cesarean delivery. Severe neonatal anemia was identified, and evaluation of maternal blood was consistent with massive FMH. This is the first reported association between FMH and IUPC placement. If this relationship is validated in future reports, appropriate changes in clinical practice may be warranted.
    09/2015; 2015(3):348279. DOI:10.1155/2015/348279
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Fetal growth is associated with long-term health yet no appropriate standards exist for the early identification of undergrown or overgrown fetuses. We sought to develop contemporary fetal growth standards for 4 self-identified US racial/ethnic groups. Study design: We recruited for prospective follow-up 2334 healthy women with low-risk, singleton pregnancies from 12 community and perinatal centers from July 2009 through January 2013. The cohort comprised: 614 (26%) non-Hispanic whites, 611 (26%) non-Hispanic blacks, 649 (28%) Hispanics, and 460 (20%) Asians. Women were screened at 8w0d to 13w6d for maternal health status associated with presumably normal fetal growth (aged 18-40 years; body mass index 19.0-29.9 kg/m(2); healthy lifestyles and living conditions; low-risk medical and obstetrical history); 92% of recruited women completed the protocol. Women were randomized among 4 ultrasonography schedules for longitudinal fetal measurement using the Voluson E8 (GE Healthcare, Milwaukee, WI). In-person interviews and anthropometric assessments were conducted at each visit; medical records were abstracted. The fetuses of 1737 (74%) women continued to be low risk (uncomplicated pregnancy, absent anomalies) at birth, and their measurements were included in the standards. Racial/ethnic-specific fetal growth curves were estimated using linear mixed models with cubic splines. Estimated fetal weight (EFW) and biometric parameter percentiles (5th, 50th, 95th) were determined for each gestational week and comparisons made by race/ethnicity, with and without adjustment for maternal and sociodemographic factors. Results: EFW differed significantly by race/ethnicity >20 weeks. Specifically at 39 weeks, the 5th, 50th, and 95th percentiles were 2790, 3505, and 4402 g for white; 2633, 3336, and 4226 g for Hispanic; 2621, 3270, and 4078 g for Asian; and 2622, 3260, and 4053 g for black women (adjusted global P < .001). For individual parameters, racial/ethnic differences by order of detection were: humerus and femur lengths (10 weeks), abdominal circumference (16 weeks), head circumference (21 weeks), and biparietal diameter (27 weeks). The study-derived standard based solely on the white group erroneously classifies as much as 15% of non-white fetuses as growth restricted (EFW <5th percentile). Conclusion: Significant differences in fetal growth were found among the 4 groups. Racial/ethnic-specific standards improve the precision in evaluating fetal growth.
    American journal of obstetrics and gynecology 09/2015; 213(4):449.e1-449.e41. DOI:10.1016/j.ajog.2015.08.032 · 4.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECT The Management of Myelomeningocele Study (MOMS) was a multicenter randomized trial comparing the safety and efficacy of prenatal and postnatal closure of myelomeningocele. The trial was stopped early because of the demonstrated efficacy of prenatal surgery, and outcomes on 158 of 183 pregnancies were reported. Here, the authors update the 1-year outcomes for the complete trial, analyze the primary and related outcomes, and evaluate whether specific prerandomization risk factors are associated with prenatal surgery benefit. METHODS The primary outcome was a composite of fetal loss or any of the following: infant death, CSF shunt placement, or meeting the prespecified criteria for shunt placement. Primary outcome, actual shunt placement, and shunt revision rates for prenatal versus postnatal repair were compared. The shunt criteria were reassessed to determine which were most concordant with practice, and a new composite outcome was created from the primary outcome by replacing the original criteria for CSF shunt placement with the revised criteria. The authors used logistic regression to estimate whether there were interactions between the type of surgery and known prenatal risk factors (lesion level, gestational age, degree of hindbrain herniation, and ventricle size) for shunt placement, and to determine which factors were associated with shunting among those infants who underwent prenatal surgery. RESULTS Ninety-one women were randomized to prenatal surgery and 92 to postnatal repair. The primary outcome occurred in 73% of infants in the prenatal surgery group and in 98% in the postnatal group (p < 0.0001). Actual rates of shunt placement were only 44% and 84% in the 2 groups, respectively (p < 0.0001). The authors revised the most commonly met criterion to require overt clinical signs of increased intracranial pressure, defined as split sutures, bulging fontanelle, or sunsetting eyes, in addition to increasing head circumference or hydrocephalus. Using these modified criteria, only 3 patients in each group met criteria but did not receive a shunt. For the revised composite outcome, there was a difference between the prenatal and postnatal surgery groups: 49.5% versus 87.0% (p < 0.0001). There was also a significant reduction in the number of children who had a shunt placed and then required a revision by 1 year of age in the prenatal group (15.4% vs 40.2%, relative risk 0.38 [95% CI 0.22-0.66]). In the prenatal surgery group, 20% of those with ventricle size < 10 mm at initial screening, 45.2% with ventricle size of 10 up to 15 mm, and 79.0% with ventricle size ≥ 15 mm received a shunt, whereas in the postnatal group, 79.4%, 86.0%, and 87.5%, respectively, received a shunt (p = 0.02). Lesion level and degree of hind-brain herniation appeared to have no effect on the eventual need for shunting (p = 0.19 and p = 0.13, respectively). Similar results were obtained for the revised outcome. CONCLUSIONS Larger ventricles at initial screening are associated with an increased need for shunting among those undergoing fetal surgery for myelomeningocele. During prenatal counseling, care should be exercised in recommending prenatal surgery when the ventricles are 15 mm or larger because prenatal surgery does not appear to improve outcome in this group. The revised criteria may be useful as guidelines for treating hydrocephalus in this group.
    Journal of Neurosurgery Pediatrics 09/2015; DOI:10.3171/2015.7.PEDS15336 · 1.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Following treatment sufficient to normalize thyrotropin (TSH), non-pregnant hypothyroid adults display higher free thyroxine (fT4) concentrations than a reference population. Our aim is to determine whether fT4 concentrations are higher during pregnancy among women treated for hypothyroidism and whether their weight is associated with fT4 levels. Weight/fT4 relationships have not previously been reported in treated hypothyroid adults (either pregnant or non-pregnant). Thyroid-related measurements were available from over 10,000 women at two early pregnancy time periods; FaSTER (First and Second Trimester Evaluation of Risk for Fetal aneuploidy) trial (1999 through 2002). All women were receiving routine prenatal care. Present analyses were restricted to 9,257 reference women and 306 treated, hypothyroid women with TSH between the 2nd and 98th reference centiles. We compared fT4 values between those groups at 11-14 and 15-18 weeks' gestation, using linear regression to estimate fT4/maternal weight relationships, after accounting for treatment and other potential covariates. In comparison to reference women, median fT4 values and percent of fT4 values ≥95th reference centile are significantly higher in treated women at both 11-14 and 15-18 weeks' gestation (p<0.001), overall, and after stratification by weight into tertiles. Among both treated and reference women, median fT4 decreases monotonically with increasing weight, regardless of thyroperoxidase antibody status. Maternal age, maternal weight, and treatment status are important predictors of fT4 levels (p<0.001, defined by partial r2 values of 1% or higher). TPO antibody status, TSH values (after logarithmic transformation), and all interaction terms are well below r2 of 1%. fT4 levels are 1.45 pmol/L higher in treated than referent women, independent of other factors. Maternal age and weight reduce fT4 levels by 0.0694 pmol/L/year and 0.0208 pmol/L/Kg, respectively. fT4 concentrations are higher among treated hypothyroid pregnant women than among referent women, and higher maternal weight is associated with lower fT4 levels, regardless of treatment status. This inverse relationship is not associated with higher TSH levels. While no immediate clinical implications are attached to the current observations, increased peripheral deiodinase activity in the presence of higher weight might explain these findings. Further investigation appears worthy of attention.
    Thyroid: official journal of the American Thyroid Association 05/2015; 25(8). DOI:10.1089/thy.2015.0085 · 4.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Given that cesarean delivery is one of the most commonly performed surgical procedures in the United States and an important contributor to obstetric care costs, this analysis sought to examine maternal hospital costs associated with trial of labor after cesarean delivery (TOLAC) versus repeat cesarean delivery (RCD). A national sample was used to identify women with singleton pregnancy who underwent either TOLAC or RCD from 2006 to 2012. Women with diagnoses that could confound cost via extended hospital length of stay prior to delivery were excluded. Other medical and obstetric covariates that could influence cost were included in an adjusted model. A total of 485 247 women were identified, including 365 596 (75.3%) cesarean deliveries without labor, 41 988 (8.6%) successful and 77 663 (16.0%) unsuccessful TOLAC deliveries. The inflation-adjusted median costs in this cohort were $5512 for cesarean without labor, $4175 for successful TOLAC, $5166 for all TOLAC attempts, and $5759 for failed TOLAC. In a multivariable model, hospital region was a major predictor of median cost as were demographic variables and medical comorbidities. TOLAC is associated with modest reductions of cost for maternal hospitalizations. However, other medical, demographic and hospital factors appear to be more important factors.
    The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 04/2015; DOI:10.3109/14767058.2015.1035250 · 1.37 Impact Factor

  • JAMA The Journal of the American Medical Association 01/2015; 313(2):197-9. DOI:10.1001/jama.2014.14774 · 35.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Although major international guidelines recommend venous thromboembolism (VTE) prophylaxis during vaginal delivery hospitalization for women with additional risk factors, US guidelines recommend prophylaxis for a very small number of women who are at particularly high risk for an event. The purpose of this study was to characterize practice patterns of VTE prophylaxis in the United States during vaginal delivery hospitalizations and to determine VTE incidence in this population. Study design: A population-level database was used to analyze VTE incidence and use of VTE prophylaxis during vaginal delivery hospitalizations in the United States between 2006 and 2012 (n = 2,673,986). We evaluated whether patients received either pharmacologic or mechanical prophylaxis. Hospital-level factors and patient characteristics were included in multivariable regression analysis that evaluated prophylaxis administration. Results: We identified 2,673,986 women who underwent vaginal delivery. Incidence of VTE increased during the study period from 15.6-29.8 events per 100,000 delivery hospitalizations. Within the cohort, 2.6% of patients (n = 68,835) received VTE prophylaxis. Pharmacologic prophylaxis was rare; <1% of women received unfractionated or low-molecular-weight heparin. Although patients with thrombophilia or a previous VTE event were likely to receive prophylaxis (60.8% and 72.8%, respectively), patients with risk factors for VTE such as obesity, smoking, and heart disease were unlikely to receive prophylaxis (rates of 5.9%, 3.3%, and 6.2%, respectively). Conclusion: Our findings demonstrate that the administration of VTE prophylaxis outside a small group of women at extremely high risk for VTE is rare during vaginal delivery hospitalization. Given that VTE incidence is rising in this population, further research to determine whether broadening prophylaxis for VTE may reduce severe maternal morbidity and death is indicated.
    American Journal of Obstetrics and Gynecology 09/2014; 212(2). DOI:10.1016/j.ajog.2014.09.017 · 4.70 Impact Factor

  • Obstetrics and Gynecology 04/2014; 123(4):896-901. · 5.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objective Our survey aimed to identify knowledge and application of guidelines in the United States by assessing practicing obstetricians and gynecologists (OBGYN) use of thromboprophylaxis, preferred methods, and whether their type of practice influenced their choices. Study Design A cross sectional survey of fellows of the American College of Obstetricians and Gynecologists (ACOG) was performed. A 21-item paper and electronic questionnaire was sent to each participant. A total of 3 mailings were carried out. Results 400 OBGYN were invited to participate. Questionnaires were returned by 209 (52.3%), 157 (75.1%) of whom provided prenatal care within the last year. All respondents used at least one method of thromboprophylaxis routinely. 92.4% used pneumatic compression devices. An equal proportion used unfractionated heparin and low molecular weight heparin routinely (17.8%). 19.1% routinely used combination prophylaxis. 77.1% (n=121) used the ACOG guideline. Local hospital guidelines were referenced by 38.2% (n=60). Other guidelines referenced were the ACCP guideline (n=34, 21.7%), and several international guidelines (n=5, 3.3%). Conclusion Awareness of the risk of thromboembolism around delivery by cesarean section is high amongst OBGYN practitioners. Broadening guidelines to encompass all deliveries, not only caesareans, with a focus on identifying the patient at risk, would likely be successful.
    The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 03/2014; 27(18). DOI:10.3109/14767058.2014.898057 · 1.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context: Lower birthweight has been reported in conjunction with high maternal free thyroxine (FT4) in euthyroid pregnancies, raising concerns for suboptimal outcomes. Objective: Explore relationships between high maternal FT4 and pregnancy complications in euthyroid women. Further examine relationships among maternal size, FT4 and birthweight. Design: Observational multicenter cohort study. Setting: Prenatal clinics. Study Subjects: 9209 euthyroid women with singleton pregnancies. Interventions: None. Main Outcome Measures: Relationships between second trimester high maternal FT4 and pregnancy/delivery complications, and among FT4, maternal weight and birthweight. Results: Women in the highest FT4 quintile are younger and weigh less than women in quintiles 1-4; gestational diabetes and preeclampsia occur less often (p = < 0.001, < 0.001, < 0.001, and 0.05, respectively). Lowest median birthweight occurs among women in the highest FT4 quintile (p = < 0.001), but deliveries < 37 weeks' gestation are not increased. Labor/delivery complications do not differ by FT4 quintile. Restricting analyses to maternal weight-adjusted small-for-gestational-age deliveries yields similar results, except for preeclampsia. In the highest maternal weight decile, adjusted median birthweight is 266g higher (8.3%) than in the lowest weight decile; adjusted median FT4 is 0.91 pmol/L lower (6.8%). Among women in the highest FT4 decile, adjusted median birthweight is 46g lower (1.3%) than in the lowest FT4 decile. All three relationships are statistically significant (p = < 0.001, < 0.001, and 0.004, respectively). Conclusions: Lower median birthweight among euthyroid women with high FT4 is not associated with adverse pregnancy outcomes. Further investigation is indicated to determine how variations in thyroid hormone concentration influence birthweight.
    The Journal of Clinical Endocrinology and Metabolism 02/2014; 99(6):jc20141053. DOI:10.1210/jc.2014-1053 · 6.21 Impact Factor

  • American Journal of Obstetrics and Gynecology 01/2014; 210(1):S260-S261. DOI:10.1016/j.ajog.2013.10.562 · 4.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To critically evaluate current understanding of risk factors for pregnancy-associated venous thromboembolism (VTE) and to describe underlying molecular mechanisms. A literature search was undertaken using the national library of medicine PubMed database. The search terms used were “pregnancy” and “venous thromboembolism”. Following exclusion of unsuitable data sources, studies were identified that described specific risk factors for pregnancy-associated VTE and suggested possible underlying molecular mechanisms. Adjusted odds ratios and incident rate ratios for these specific risk factors were identified in each study and tabulated. A series of mainly retrospective cohort and case control studies over the past two decades have reported specific risk factors for pregnancy-associated VTE. Recent published literature has highlighted the interaction between commonly occurring risk factors, particularly the potential for a multiplicative effect on overall VTE risk, and have led to improvements in our understanding of the molecular mechanisms underlying these risk factors. Mortality from pregnancy associated VTE continues despite prevention strategies. A detailed understanding of specific risk factors, their interactions and underlying molecular mechanisms is required to identify women at highest risk and to guide development of thromboprophylaxis strategies.
    Journal of Perinatal Medicine 12/2013; 42(4):1-9. DOI:10.1515/jpm-2013-0207 · 1.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To characterize contemporary practice patterns for postcesarean thromboembolism prophylaxis and determine whether opportunities to substantially decrease maternal mortality and morbidity in this clinical setting are being missed. A commercial hospitalization database that includes procedure and diagnosis codes, health care provider and hospital information, and patient demographic data were used to analyze use of venous thromboembolism prophylaxis after cesarean delivery in the United States between 2003 and 2010. The analysis evaluated whether patients received pharmacologic prophylaxis, mechanical prophylaxis, combined prophylaxis, or no prophylaxis. Hospital-level factors and patient characteristics were included in multivariable regression models evaluating prophylaxis administration. We identified 1,263,205 women who underwent cesarean delivery. Within the cohort, 75.7% (n=955,787) received no thromboembolism prophylaxis, 22.1% (n=278,669) received mechanical prophylaxis alone, 1.3% (n=16,639) received pharmacologic prophylaxis, and 1.0% (n=12,110) received combination prophylaxis. The rate of prophylaxis increased from 8.4% in 2003 to 41.6% in 2010. Prophylaxis rates varied significantly by geographic region. Medical risk factors for thromboembolism were associated with only modest increases in prophylaxis. Although our findings demonstrated increased adoption of postcesarean venous thromboembolism prophylaxis, fewer than half of patients received recommended care as of 2010, and significant variation was present. Thromboembolism prophylaxis is underused and represents a major opportunity to reduce maternal morbidity and mortality. Risk assessment tools and thromboprophylaxis guidelines are needed to assure high-quality, uniform care. LEVEL OF EVIDENCE:: III.
    Obstetrics and Gynecology 11/2013; 122(6). DOI:10.1097/AOG.0000000000000007 · 5.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Perinatal Quality Foundation has created an examination containing both knowledge based and judgment questions relating to the interpretation of electronic fetal heart rate monitoring for credentialing all medical and nursing personnel working on a labor and delivery floor. A description of the examination and the rationale for its use throughout the United States is presented.
    American journal of obstetrics and gynecology 10/2013; 210(3). DOI:10.1016/j.ajog.2013.10.007 · 4.70 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this Journal in 1972, 100 leaders in obstetrics and gynecology published a compelling statement that recognized the legalization of abortion in several states and anticipated the 1973 Supreme Court decision in Roe v Wade. They projected the numbers of legal abortions that likely would be required by women in the United States and described the role of the teaching hospital in meeting that responsibility. They wrote to express their concern for women's health in a new legal and medical era of reproductive control and to define the responsibilities of academic obstetrician-gynecologists. Forty years later, 100 professors examine the statement of their predecessors in light of medical advances and legal changes and suggest a further course of action for obstetrician gynecologists.
    Contraception 10/2013; 88(4):568-576. DOI:10.1016/j.contraception.2013.07.003 · 2.34 Impact Factor
  • Joy Vink · Britta Anderson · Karin Fuchs · Jay Schulkin · Mary E D'Alton ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Accurate amniocentesis-related pregnancy loss (ARL) rates for twin gestations remains elusive because of varying ARL definitions in the literature. We examined how OB/GYNs define/counsel women carrying twins about ARL. Methods: A random sample of 1000 American College of OB/GYN (ACOG) fellows and ACOG Collaborative Ambulatory Research Network (CARN) members were mailed surveys about their opinions/practice patterns regarding amniocentesis in twins. There were 208/400 (52%) CARN members and 166/600 (27%) ACOG fellows who returned the survey (37% response rate). Results: Of respondents, 80.8% practiced general OB/GYN, and 9.1% practiced maternal fetal medicine. Of respondents, 72% discussed amniocentesis for prenatal diagnosis. Of these, 91.7% discuss the risk of ARL; however, 47.4% do not quote an ARL rate. Of those who discuss ARL rates, 65% quote a rate greater than for singletons. Regarding monochorionic-diamniotic twins, 12.1% of respondents said the ARL rate was less, 39.6% said equal to, and 38.9% said greater than for dichorionic twins. Table 1 lists the most common clinical definitions/time intervals used to describe ARL. Conclusion: Various definitions/ARL rates are used when counseling about ARL in twins. Further studies using a widely accepted definition of ARL are necessary to improve the counseling of women considering amniocentesis for prenatal diagnosis in twins.
    Prenatal Diagnosis 09/2013; 33(9). DOI:10.1002/pd.4164 · 3.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the clinical outcomes and risk factors for persistence of ovarian cysts in pregnant women. With the increased use of ultrasound in pregnancy, the identification of incidental ovarian masses is becoming more common. An observational study of women with ovarian masses identified before 24 weeks of pregnancy was performed. Only women who underwent follow-up imaging or surgery were included. Factors associated with persistence and outcomes of women who underwent surgery were analyzed. Of the 803 women with available follow-up, the cysts resolved in 707 (88.1%) patients. Fifty (6.2%) women underwent surgical intervention. Women with persistent cysts were younger, more often Hispanic, detected at a later gestational age, had larger cysts, and more often had complex or solid components (p < 0.05 for all). Overall, 1 (0.1%) malignancy was diagnosed (a patient with a B-cell lymphoma), while 3 (0.4%) women had borderline epithelial ovarian tumors. Ovarian masses identified during pregnancy have a low risk of malignancy. The majority of women can be serially monitored without intervention.
    The Journal of reproductive medicine 09/2013; 58(9-10):377-82. · 0.70 Impact Factor
  • Suneet P Chauhan · Mary E D'Alton ·

    Seminars in perinatology 08/2013; 37(4):205-6. DOI:10.1053/j.semperi.2013.04.009 · 2.68 Impact Factor

Publication Stats

6k Citations
1,097.98 Total Impact Points


  • 2009-2015
    • Society for Maternal-Fetal Medicine
      New York, New York, United States
    • University of Utah
      • Department of Obstetrics and Gynecology
      Salt Lake City, UT, United States
  • 2001-2015
    • Columbia University
      • Department of Obstetrics and Gynecology
      New York, New York, United States
  • 2001-2014
    • CUNY Graduate Center
      New York, New York, United States
  • 2013
    • Gracie Square Hospital, New York, NY
      New York City, New York, United States
  • 2011
    • Alpert Medical School - Brown University
      • Department of Pathology and Laboratory Medicine
      Providence, Rhode Island, United States
  • 2010
    • Massachusetts General Hospital
      • Department of Obstetrics and Gynecology
      Boston, MA, United States
  • 1999-2010
    • Mid-Columbia Medical Center
      DLS, Oregon, United States
    • Tufts Medical Center
      Boston, Massachusetts, United States
  • 1993-2009
    • Tufts University
      • Department of Obstetrics and Gynecology
      Medford, MA, United States
  • 2008
    • University of Cambridge
      • Department of Obstetrics & Gynaecology
      Cambridge, England, United Kingdom
  • 2007
    • Texas A&M University - Galveston
      Galveston, Texas, United States
    • University of Washington Seattle
      • Department of Obstetrics and Gynecology
      Seattle, Washington, United States
  • 2006-2007
    • Boston University
      • Department of Biostatistics
      Boston, Massachusetts, United States
    • William Beaumont Army Medical Center
      El Paso, Texas, United States
    • Rotunda Hospital
      Dublin, Leinster, Ireland
  • 2004
      Newark, New Jersey, United States
  • 2003-2004
    • New York Presbyterian Hospital
      • Department of Obstetrics and Gynecology
      New York City, New York, United States
  • 1994-2000
    • University of Massachusetts Boston
      Boston, Massachusetts, United States
  • 1997
    • Dartmouth–Hitchcock Medical Center
      Lebanon, New Hampshire, United States
    • The Children's Hospital of Philadelphia
      • Center for Fetal Diagnosis and Treatment
      Filadelfia, Pennsylvania, United States
  • 1996
    • National Maternity Hospital
      Dublin, Leinster, Ireland
    • Boston Children's Hospital
      • Department of Pediatrics
      Boston, MA, United States